University of Texas/Texas AM Investment Management Co (UTIMCO)’s BioCryst Pharmaceuticals BCRX Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-90,977	Closed	-$866K	–	429
2026 Q1	$866K	Buy	90,977 +26,470	+41%	+$206K	0.13%	98
2025 Q4	$503K	Buy	+64,507	New	+$466K	0.07%	124

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s BCRX Position: Q2 2026 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 90,977 shares — an estimated $866K sold.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in BCRX in Q4 2025 and held it in 2 quarters. The position peaked at $866K in Q1 2026. 189 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

University of Texas/Texas AM Investment Management Co (UTIMCO) reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
University of Texas/Texas AM Investment Management Co (UTIMCO) sold 90,977 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $866K.
University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 2 quarters.
University of Texas/Texas AM Investment Management Co (UTIMCO)'s BioCryst Pharmaceuticals position peaked at $866K in Q1 2026.
189 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q2 2026, filed 3 Aug 2026.